Trial Profile

Denosumab in the prevention of immobilization-induced bone loss in Intensive Care Unit patients

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Denosumab (Primary)
Indications Bone resorption
Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

01 Nov 2022 Primary endpoint has been met, (a) Serum levels of carboxy-terminal collagen crosslinks (CTX-1) one month after first denosumab application, as per Results published in the Journal of Bone and Mineral Research
01 Nov 2022 Results published in the Journal of Bone and Mineral Research
24 Jul 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com